-
Je něco špatně v tomto záznamu ?
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity
L. Zatloukalová, T. Filipský, P. Mladěnka, V. Semecký, K. Macáková, M. Holečková, J. Vávrová, V. Palicka, R. Hrdina,
Jazyk angličtina Země Kanada
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
22439652
DOI
10.1139/y2012-009
Knihovny.cz E-zdroje
- MeSH
- chelátory železa farmakologie MeSH
- hemodynamika účinky léků MeSH
- infarkt myokardu chemicky indukované farmakoterapie MeSH
- isoprenalin antagonisté a inhibitory MeSH
- kardiotonika farmakologie terapeutické užití MeSH
- krysa rodu rattus MeSH
- modely nemocí na zvířatech MeSH
- myokard metabolismus patologie MeSH
- potkani Wistar MeSH
- razoxan farmakologie terapeutické užití MeSH
- vápník metabolismus MeSH
- železo metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Positive effects of dexrazoxane (DEX) in anthracycline cardiotoxicity have been mostly assumed to be associated with its iron-chelating properties. However, this explanation has been recently questioned. Iron plays also an important role in the catecholamine cardiotoxicity. Hence in this study, the influence of DEX on a catecholamine model of acute myocardial infarction (100 mg/kg of isoprenaline by subcutaneous injection) was assessed: (i) the effects of an intravenous dose of 20.4 mg/kg were analyzed after 24 h, (ii) the effects were monitored continuously during the first two hours after drug(s) administration to examine the mechanism(s) of cardioprotection. Additional in vitro experiments on iron chelation/reduction and influence on the Fenton chemistry were performed both with isoprenaline/DEX separately and in their combination. DEX partly decreased the mortality, reduced myocardial calcium overload, histological impairment, and peripheral haemodynamic disturbances 24 h after isoprenaline administration. Continuous 2 h experiments showed that DEX did not influence isoprenaline induced atrioventricular blocks and had little effect on the measured haemodynamic parameters. Its protective effects are probably mediated by inhibition of late myocardial impairment and ventricular fibrillation likely due to inhibition of myocardial calcium overload. Complementary in vitro experiments suggested that iron chelation properties of DEX apparently did not play the major role.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12034641
- 003
- CZ-PrNML
- 005
- 20121206123048.0
- 007
- ta
- 008
- 121023s2012 xxc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1139/y2012-009 $2 doi
- 035 __
- $a (PubMed)22439652
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxc
- 100 1_
- $a Zatloukalová, Libuše $u Charles University in Prague, Department of Pharmacology and Toxicology, Heyrovského, Hradec Králové, Czech Republic.
- 245 10
- $a Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity / $c L. Zatloukalová, T. Filipský, P. Mladěnka, V. Semecký, K. Macáková, M. Holečková, J. Vávrová, V. Palicka, R. Hrdina,
- 520 9_
- $a Positive effects of dexrazoxane (DEX) in anthracycline cardiotoxicity have been mostly assumed to be associated with its iron-chelating properties. However, this explanation has been recently questioned. Iron plays also an important role in the catecholamine cardiotoxicity. Hence in this study, the influence of DEX on a catecholamine model of acute myocardial infarction (100 mg/kg of isoprenaline by subcutaneous injection) was assessed: (i) the effects of an intravenous dose of 20.4 mg/kg were analyzed after 24 h, (ii) the effects were monitored continuously during the first two hours after drug(s) administration to examine the mechanism(s) of cardioprotection. Additional in vitro experiments on iron chelation/reduction and influence on the Fenton chemistry were performed both with isoprenaline/DEX separately and in their combination. DEX partly decreased the mortality, reduced myocardial calcium overload, histological impairment, and peripheral haemodynamic disturbances 24 h after isoprenaline administration. Continuous 2 h experiments showed that DEX did not influence isoprenaline induced atrioventricular blocks and had little effect on the measured haemodynamic parameters. Its protective effects are probably mediated by inhibition of late myocardial impairment and ventricular fibrillation likely due to inhibition of myocardial calcium overload. Complementary in vitro experiments suggested that iron chelation properties of DEX apparently did not play the major role.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vápník $x metabolismus $7 D002118
- 650 _2
- $a kardiotonika $x farmakologie $x terapeutické užití $7 D002316
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a hemodynamika $x účinky léků $7 D006439
- 650 _2
- $a železo $x metabolismus $7 D007501
- 650 _2
- $a chelátory železa $x farmakologie $7 D007502
- 650 _2
- $a isoprenalin $x antagonisté a inhibitory $7 D007545
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a infarkt myokardu $x chemicky indukované $x farmakoterapie $7 D009203
- 650 _2
- $a myokard $x metabolismus $x patologie $7 D009206
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a razoxan $x farmakologie $x terapeutické užití $7 D011929
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Filipský, Tomáš
- 700 1_
- $a Mladěnka, Přemysl
- 700 1_
- $a Semecký, Vladimír
- 700 1_
- $a Macáková, Kateřina
- 700 1_
- $a Holečková, Magdalena
- 700 1_
- $a Vávrová, Jaroslava
- 700 1_
- $a Palicka, Vladimir
- 700 1_
- $a Hrdina, Radomír
- 773 0_
- $w MED00001020 $t Canadian journal of physiology and pharmacology $x 1205-7541 $g Roč. 90, č. 4 (2012), s. 473-84
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22439652 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a
- 990 __
- $a 20121023 $b ABA008
- 991 __
- $a 20121206123121 $b ABA008
- 999 __
- $a ok $b bmc $g 956651 $s 792138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 90 $c 4 $d 473-84 $i 1205-7541 $m Canadian journal of physiology and pharmacology $n Can J Physiol Pharmacol $x MED00001020
- LZP __
- $a Pubmed-20121023